GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » American Bio Medica Corp (OTCPK:ABMC) » Definitions » 3-Year RORE %

American Bio Medica (American Bio Medica) 3-Year RORE % : 0.00% (As of Mar. 2023)


View and export this data going back to . Start your Free Trial

What is American Bio Medica 3-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. American Bio Medica's 3-Year RORE % for the quarter that ended in Mar. 2023 was 0.00%.

The industry rank for American Bio Medica's 3-Year RORE % or its related term are showing as below:

ABMC's 3-Year RORE % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -7.72
* Ranked among companies with meaningful 3-Year RORE % only.

American Bio Medica 3-Year RORE % Historical Data

The historical data trend for American Bio Medica's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

American Bio Medica 3-Year RORE % Chart

American Bio Medica Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 50.85 8.75 -4.35 -31.75 11.69

American Bio Medica Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -31.75 -26.76 6.49 11.69 -151.85

Competitive Comparison of American Bio Medica's 3-Year RORE %

For the Diagnostics & Research subindustry, American Bio Medica's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


American Bio Medica's 3-Year RORE % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, American Bio Medica's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where American Bio Medica's 3-Year RORE % falls into.



American Bio Medica 3-Year RORE % Calculation

American Bio Medica's 3-Year RORE % for the quarter that ended in Mar. 2023 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( 0.01--0.031 )/( -0.027-0 )
=0.041/-0.027
=-151.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2023 and 3-year before.


American Bio Medica  (OTCPK:ABMC) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


American Bio Medica 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of American Bio Medica's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


American Bio Medica (American Bio Medica) Business Description

Traded in Other Exchanges
N/A
Address
122 Smith Road, Kinderhook, New York, NY, USA, 12106
American Bio Medica Corp is a us-based company engaged in manufacturing and selling lateral flow immunoassay tests, primarily for the immediate detection of certain drugs in urine and oral fluids at the point of collection. It also manufactures and sells drug testing products and provides bulk test strip manufacturing services to unaffiliated third parties on a contract basis. The company offers few urine tests which include Rapid Drug Screen, RDS InCup, Rapid TOX, and Rapid TOX Cup II. Its target customer includes workplace, government, corrections, clinical and educational markets. Geographically, it derives a majority of revenue from the United States.
Executives
Stuart Steinberg 10 percent owner 85 BELLEVUE AVENUE, RYE NY 10580
John J Moroney 10 percent owner 118 PEGASUS DR., JUPITER FL 33477
Chaim Davis director 2601 PINE TREE DRIVE, MIAMI BEACH FL 33140
Peter Jerome director 7 RIDGECREST AVE, LATHAM NY 12110
Diane Generous director 122 SMITH ROAD, KINDERHOOK NY 12106
Melissa A Waterhouse officer: EVP, CCO, CORP SEC AMERICAN BIO MEDICA CORPORATION, 122 SMITH ROAD, KINDERHOOK NY 12106
Mp Biomedicals Llc 10 percent owner 3 HUTTON CENTRE DRIVE, SUITE 100, SANTA ANA CA 92707
Douglas Casterlin officer: Executive Vice President C/O MELISSA A. WATERHOUSE/ABMC, 122 SMITH ROAD, KINDERHOOK NY 12106
Jean Neff director C/O ABMC, 122 SMITH ROAD, KINDERHOOK NY 12106
Stefan Parker officer: Chief Financial Officer 122 SMITH ROAD, KINDERHOOK NY 12106
Carl A Florio director C/O HUDSON RIVER BANK & TRUST CO, PO BOX 76, HUDSON NY 12534
Stan Cipkowski director 300 S LAKE DR, STE 340, FISHKILL NY 12553
Anthony G Costantino director 122 SMITH ROAD, KINDERHOOK NY 12106
Edmund M Jaskiewicz director, officer: President
Richard Koskey director C/O ABMC 122 SMITH ROAD, 122 SMITH ROAD, KINDERHOOK NY 12106

American Bio Medica (American Bio Medica) Headlines

From GuruFocus

ABMC Uplists to the OTCQB Venture Market

By ACCESSWIRE ACCESSWIRE 12-02-2020

ABMC Reports First Quarter 2021 Results

By ACCESSWIRE ACCESSWIRE 05-21-2021

ABMC Distributes Rapid Antigen Test For Covid-19

By ACCESSWIRE ACCESSWIRE 12-14-2020

ABMC Reports Second Quarter 2021 Results

By ACCESSWIRE ACCESSWIRE 08-18-2021

ABMC Reports Third Quarter 2021 Results

By ACCESSWIRE ACCESSWIRE 11-18-2021

ABMC Reports First Quarter 2020 Results

By ACCESSWIRE ACCESSWIRE 08-01-2020